Spruce Biosciences Sets New Director Compensation Terms with Stock Options and Retainers

Reuters
Dec 15
<a href="https://laohu8.com/S/SPRB">Spruce Biosciences</a> Sets New Director Compensation Terms with Stock Options and Retainers

Spruce Biosciences Inc. has appointed Keli Walbert to its board of directors, effective immediately. As part of the company's non-employee director compensation policy, Walbert has been granted a nonstatutory stock option to purchase 3,400 shares of common stock, vesting monthly over three years. She will receive an annual cash retainer of $40,000 for her role as director and $5,000 for serving on the Compensation Committee, both pro-rated for 2025. Starting January 1, 2026, the Compensation Committee retainer will increase to $5,500. From the 2026 Annual Meeting, Walbert will also be eligible for an annual stock option to purchase 1,700 shares, vesting by the next annual meeting or one year from grant, whichever comes first.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-318488), on December 15, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10